Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
DNA Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call reveals improvements in financial metrics, including reduced operating losses and cash burn due to restructuring. Although revenue decreased, optimistic guidance and strategic initiatives in AI and robotics present potential growth avenues. The Q&A section highlights positive reception of new services and potential revenue tailwinds. However, management's vague response on U.S. onshoring introduces some uncertainty. Overall, the positive elements, such as improved financial health and strategic growth plans, outweigh negatives, suggesting a likely positive stock price movement.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
Earnings call transcript: Ginkgo Bioworks’ Q1 2025 revenue rises, stock slips
Positive5-6
The earnings call reveals positive financial performance with significant cost reductions, strong revenue growth in cell engineering, and improved EBITDA. The company has a solid cash position and no bank debt. Despite some uncertainties in the Q&A, the ARPA H contract and government projects provide revenue stability. The company is also exploring new opportunities in SaaS and automation, which could drive future growth. The overall sentiment is positive, with potential for stock price appreciation.
DNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
